Lilly's Omvoh receives US FDA approval to treat Crohn's disease in adults: Indianapolis Friday, January 17, 2025, 12:00 Hrs [IST] Eli Lilly and Company announced that the US Food ...

Learn why clinical trials are crucial for medical advancements and how to navigate participation. Find out more about IBD ...

Jane Searfoss was inspired to become a child life specialist at Boston Children's Hospital because of her own experience ...

Wearable devices can identify, differentiate, and predict flare-ups, or the worsening of symptoms and inflammation, in inflammatory bowel disease (IBD), Mount Sinai researchers have shown in a ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...

Researchers have described the neurodegeneration that occurs in the nervous system of the bowel in Batten disease, a rare and fatal genetic condition. In their latest study, a team showed that gene ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...

Mirikizumab is a humanized immunoglobulin G4 monoclonal antibody that selectively binds to the p19 subunit of human interleukin (IL)-23.

In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic respons ...

"Our study suggests that vedolizumab is a viable option for induction and long-term maintenance therapy in children with IBD, ...

The multicentre, prospective, cohort study by Ohad Atia and colleagues1 on the long-term efficacy and safety of maintenance vedolizumab in paediatric patients with inflammatory bowel disease (IBD) ...

Children diagnosed with inflammatory bowel disease (IBD) face a significantly higher risk for venous thromboembolism (VTE) ...